Form 4: Helix Acquisition Corp. II COO Reports Stock Transaction
Insider Transaction (Form 4)
Idan Elmelech, COO & Principal Financial Ofcr of Helix Acquisition Corp. II, reported a transaction in 343 shares of common stock on October 1, 2026.
Summary
- Tax/exercise-price withholding: disposed of 343 Common Stock at $3.94 ($1,351) on October 1, 2026; holds 14,152 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Idan Elmelech — Officer (COO & Principal Financial Ofcr)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Tax/exercise-price withholding | Common Stock | 343 | $4 | $1.4K | 14,152 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Tax/exercise-price withholding (343 shares) |
Keywords
insider transaction, Form 4, BBOT, BridgeBio Oncology Therapeutics, Inc., neutral, Idan Elmelech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.